»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
½Å°æÅðÇ༺ Áúȯ Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â 248¾ï 5,220¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ µ¿¾È 9.1%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¼¼°èÀÇ ½Å°æÅðÇ༺ Áúȯ Ä¡·áÁ¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´ë»óÀ¸·Î ÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº °·ÂÇÑ ÀǾàǰ °³¹ß ÆÄÀÌÇÁ¶óÀÎ, ½Å°æÅðÇ༺ Áúȯ¿¡ ´ëÇÑ ³ôÀº ¿¬±¸ ÀÚ±Ý, °í°¨µµ Áø´Ü ¾ç½ÄÀÇ °¡¿ë¼º¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ
2025³â
Á¾·á ¿¬µµ
2029³â
¿¹Ãø ±â°£
2025-2029³â
¼ºÀå ¸ð¸àÅÒ
°¡¼Ó
YOY 2025
8%
CAGR
9.1%
Áõ°¡¾×
248¾ï 5,220¸¸ ´Þ·¯
ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. º¸°í¼¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ª ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.
º» Á¶»ç´Â °í·ÉÈ Àα¸ Áõ°¡°¡ ÇâÈÄ ¸î ³â°£ ½Å°æÅðÇ༺ Áúȯ Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª¶ó°í ÁöÀûÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æÅðÇ༺ ÁúȯÀÇ À¯ÀüÀû ±â¹Ý ¹× ºÐÀÚÀû º´Å¿¡ ´ëÇÑ ÀÌÇØÀÇ Çâ»ó°ú ³ôÀº °æÁ¦Àû ºÎ´ãÀº ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå Technavio ºÐ¼®
°¡°Ý, ¼ö¸íÁÖ±â, °í°´ ±¸ÀÔ ¹Ù½ºÄÏ, äÅà ºñÀ², ±¸ÀÔ ±âÁØ ºÐ¼®
ÀÎDzÀÇ Á߿伺°ú Â÷º°È ¿äÀÎ
È¥¶õ ¿äÀÎ
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
Á¦3Àå ½ÃÀå ±¸µµ
½ÃÀå »ýŰè
½ÃÀå Æ¯Â¡
¹ë·ùüÀÎ ºÐ¼®
Á¦4Àå ½ÃÀå ±Ô¸ð
½ÃÀåÀÇ Á¤ÀÇ
½ÃÀå ºÎ¹® ºÐ¼®
½ÃÀå ±Ô¸ð(2024³â)
½ÃÀå Àü¸Á(2024-2029³â)
Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû
½Å°æÅðÇ༺ Áúȯ Ä¡·áÁ¦ ½ÃÀå(2019-2023³â)
ÀûÀÀÁõº° ºÎ¹® ºÐ¼®(2019-2023³â)
¾àÁ¦ Ŭ·¡½ºº° ºÎ¹® ºÐ¼®(2019-2023³â)
Åõ¿© °æ·Îº° ºÎ¹® ºÐ¼®(2019-2023³â)
ÃÖÁ¾»ç¿ëÀÚº° ºÎ¹® ºÐ¼®(2019-2023³â)
Áö¿ªº° ºÎ¹® ºÐ¼®(2019-2023³â)
±¹°¡º° ºÎ¹® ºÐ¼®(2019-2023³â)
Á¦6Àå Á¤¼º ºÐ¼®
AIÀÇ ¿µÇâ : ½Å°æÅðÇ༺ Áúȯ Ä¡·áÁ¦ ½ÃÀå
Á¦7Àå Five Forces ºÐ¼®
Five Forces ¿ä¾à
¹ÙÀ̾îÀÇ ±³¼··Â
°ø±Þ ±â¾÷ÀÇ ±³¼··Â
½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
´ëüǰÀÇ À§Çù
°æÀï À§Çù
½ÃÀå ÇöȲ
Á¦8Àå ½ÃÀå ¼¼ºÐÈ : ÀûÀÀÁõº°
½ÃÀå ºÎ¹®
ºñ±³ : ÀûÀÀÁõº°
´Ù¹ß¼º °æÈÁõ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¾ËÃ÷ÇÏÀ̸Ӻ´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÆÄŲ½¼º´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÇåÆÃÅϺ´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : ÀûÀÀÁõº°
Á¦9Àå ½ÃÀå ¼¼ºÐÈ : ¾àÁ¦ Ŭ·¡½ºº°
½ÃÀå ºÎ¹®
ºñ±³ : ¾àÁ¦ Ŭ·¡½ºº°
¸é¿ªÁ¶ÀýÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀÎÅÍÆä·Ð : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Żź»ê È¿¼Ò ¾ïÁ¦Á¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
µµÆÄ¹Î ÀÛ¿ëÁ¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : ¾àÁ¦ Ŭ·¡½ºº°
Á¦10Àå ½ÃÀå ¼¼ºÐÈ : Åõ¿© °æ·Îº°
½ÃÀå ºÎ¹®
ºñ±³ : Åõ¿© °æ·Îº°
°æ±¸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÁÖ»ç : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
°æÇÇ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Åõ¿© °æ·Îº°
Á¦11Àå ½ÃÀå ¼¼ºÐÈ : ÃÖÁ¾»ç¿ëÀÚº°
½ÃÀå ºÎ¹®
ºñ±³ : ÃÖÁ¾»ç¿ëÀÚº°
º´¿ø ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¼Ò¸Å ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¿Â¶óÀÎ ¾à±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : ÃÖÁ¾»ç¿ëÀÚº°
Á¦12Àå °í°´ »óȲ
Á¦13Àå Áö¿ªº° »óȲ
Áö¿ªº° ¼¼ºÐÈ
Áö¿ªº° ºñ±³
ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¼¼°è ±âŸ Áö¿ª : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Áß±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÇÁ¶û½º : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Àεµ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
ÀÌÅ»¸®¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
Çѱ¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2024-2029³â)
½ÃÀå ±âȸ : Áö¿ª »óȲº°
Á¦14Àå ¼ºÀå, ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ ¹× ¼ºÀå ¾ïÁ¦¿äÀÎ
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
½ÃÀå ±âȸ¿Í ¼ºÀå ¾ïÁ¦¿äÀÎ
Á¦15Àå °æÀï ±¸µµ
°³¿ä
°æÀï ±¸µµ
ÆÄ±«Àû Çõ½Å »óȲ
¾÷°è ¸®½ºÅ©
Á¦16Àå °æÀï ºÐ¼®
±â¾÷ °³¿ä
±â¾÷ ¼øÀ§ Áö¼ö
±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
AstraZeneca Plc
Biogen Inc.
F. Hoffmann La Roche Ltd.
GlaxoSmithKline Plc
H Lundbeck AS
Johnson and Johnson Services Inc.
Merck and Co. Inc.
Mitsubishi Chemical Corp.
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
Á¦17Àå ºÎ·Ï
LSH
The neurodegenerative diseases therapeutics market is forecasted to grow by USD 24852.2 mn during 2024-2029, accelerating at a CAGR of 9.1% during the forecast period. The report on the neurodegenerative diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by strong drug development pipeline, high research funding on neurodegenerative diseases, and availability of highly sensitive diagnostic modalities.
Market Scope
Base Year 2025
End Year 2029
Series Year 2025-2029
Growth Momentum Accelerate
YOY 2025 8%
CAGR 9.1%
Incremental Value $24852.2 mn
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's neurodegenerative diseases therapeutics market is segmented as below:
By Indication
Multiple sclerosis
Alzheimers disease
Parkinsons disease
Huntingtons disease
Others
By Drug Class
Immunomodulators
Interferons
Decarboxylase inhibitors
Dopamine agonists
Others
By Route Of Administration
Oral
Injection
Transdermal
By End-user
Hospital pharmacy
Retail pharmacy
Online pharmacy
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)
This study identifies the increase in aging population as one of the prime reasons driving the neurodegenerative diseases therapeutics market growth during the next few years. Also, improved understanding of genetic basis and molecular pathology of neurodegenerative diseases and high economic burden will lead to sizable demand in the market.
The report on the neurodegenerative diseases therapeutics market covers the following areas:
Neurodegenerative Diseases Therapeutics Market sizing
Neurodegenerative Diseases Therapeutics Market forecast
Neurodegenerative Diseases Therapeutics Market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading neurodegenerative diseases therapeutics market vendors that include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., AstraZeneca Plc, Biogen Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Chemical Corp., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.. Also, the neurodegenerative diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Indication
Executive Summary - Chart on Market Segmentation by Drug Class
Executive Summary - Chart on Market Segmentation by Route of Administration
Executive Summary - Chart on Market Segmentation by End-user
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
Overview on factors of disruption
2.4 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
3.1 Market ecosystem
Parent Market
Data Table on - Parent Market
3.2 Market characteristics
Market characteristics analysis
3.3 Value chain analysis
4 Market Sizing
4.1 Market definition
Offerings of companies included in the market definition
4.2 Market segment analysis
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
Chart on Global - Market size and forecast 2024-2029 ($ million)
Data Table on Global - Market size and forecast 2024-2029 ($ million)
Chart on Global Market: Year-over-year growth 2024-2029 (%)
Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
5.1 Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023
Historic Market Size - Data Table on Global Neurodegenerative Diseases Therapeutics Market 2019 - 2023 ($ million)
5.2 Indication segment analysis 2019 - 2023
Historic Market Size - Indication Segment 2019 - 2023 ($ million)
5.3 Drug Class segment analysis 2019 - 2023
Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.4 Route of Administration segment analysis 2019 - 2023
Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
5.5 End-user segment analysis 2019 - 2023
Historic Market Size - End-user Segment 2019 - 2023 ($ million)
5.6 Geography segment analysis 2019 - 2023
Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.7 Country segment analysis 2019 - 2023
Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
6.1 Impact of AI in global neurodegenerative diseases therapeutics market
7 Five Forces Analysis
7.1 Five forces summary
Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Indication
8.1 Market segments
Chart on Indication - Market share 2024-2029 (%)
Data Table on Indication - Market share 2024-2029 (%)
8.2 Comparison by Indication
Chart on Comparison by Indication
Data Table on Comparison by Indication
8.3 Multiple sclerosis - Market size and forecast 2024-2029
Chart on Multiple sclerosis - Market size and forecast 2024-2029 ($ million)
Data Table on Multiple sclerosis - Market size and forecast 2024-2029 ($ million)
Chart on Multiple sclerosis - Year-over-year growth 2024-2029 (%)
Data Table on Multiple sclerosis - Year-over-year growth 2024-2029 (%)
8.4 Alzheimers disease - Market size and forecast 2024-2029
Chart on Alzheimers disease - Market size and forecast 2024-2029 ($ million)
Data Table on Alzheimers disease - Market size and forecast 2024-2029 ($ million)
Chart on Alzheimers disease - Year-over-year growth 2024-2029 (%)
Data Table on Alzheimers disease - Year-over-year growth 2024-2029 (%)
8.5 Parkinsons disease - Market size and forecast 2024-2029
Chart on Parkinsons disease - Market size and forecast 2024-2029 ($ million)
Data Table on Parkinsons disease - Market size and forecast 2024-2029 ($ million)
Chart on Parkinsons disease - Year-over-year growth 2024-2029 (%)
Data Table on Parkinsons disease - Year-over-year growth 2024-2029 (%)
8.6 Huntingtons disease - Market size and forecast 2024-2029
Chart on Huntingtons disease - Market size and forecast 2024-2029 ($ million)
Data Table on Huntingtons disease - Market size and forecast 2024-2029 ($ million)
Chart on Huntingtons disease - Year-over-year growth 2024-2029 (%)
Data Table on Huntingtons disease - Year-over-year growth 2024-2029 (%)
8.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
8.8 Market opportunity by Indication
Market opportunity by Indication ($ million)
Data Table on Market opportunity by Indication ($ million)
9 Market Segmentation by Drug Class
9.1 Market segments
Chart on Drug Class - Market share 2024-2029 (%)
Data Table on Drug Class - Market share 2024-2029 (%)
9.2 Comparison by Drug Class
Chart on Comparison by Drug Class
Data Table on Comparison by Drug Class
9.3 Immunomodulators - Market size and forecast 2024-2029
Chart on Immunomodulators - Market size and forecast 2024-2029 ($ million)
Data Table on Immunomodulators - Market size and forecast 2024-2029 ($ million)
Chart on Immunomodulators - Year-over-year growth 2024-2029 (%)
Data Table on Immunomodulators - Year-over-year growth 2024-2029 (%)
9.4 Interferons - Market size and forecast 2024-2029
Chart on Interferons - Market size and forecast 2024-2029 ($ million)
Data Table on Interferons - Market size and forecast 2024-2029 ($ million)
Chart on Interferons - Year-over-year growth 2024-2029 (%)
Data Table on Interferons - Year-over-year growth 2024-2029 (%)
9.5 Decarboxylase inhibitors - Market size and forecast 2024-2029
Chart on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million)
Data Table on Decarboxylase inhibitors - Market size and forecast 2024-2029 ($ million)
Chart on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%)
Data Table on Decarboxylase inhibitors - Year-over-year growth 2024-2029 (%)
9.6 Dopamine agonists - Market size and forecast 2024-2029
Chart on Dopamine agonists - Market size and forecast 2024-2029 ($ million)
Data Table on Dopamine agonists - Market size and forecast 2024-2029 ($ million)
Chart on Dopamine agonists - Year-over-year growth 2024-2029 (%)
Data Table on Dopamine agonists - Year-over-year growth 2024-2029 (%)
9.7 Others - Market size and forecast 2024-2029
Chart on Others - Market size and forecast 2024-2029 ($ million)
Data Table on Others - Market size and forecast 2024-2029 ($ million)
Chart on Others - Year-over-year growth 2024-2029 (%)
Data Table on Others - Year-over-year growth 2024-2029 (%)
9.8 Market opportunity by Drug Class
Market opportunity by Drug Class ($ million)
Data Table on Market opportunity by Drug Class ($ million)
10 Market Segmentation by Route of Administration
10.1 Market segments
Chart on Route of Administration - Market share 2024-2029 (%)
Data Table on Route of Administration - Market share 2024-2029 (%)
10.2 Comparison by Route of Administration
Chart on Comparison by Route of Administration
Data Table on Comparison by Route of Administration
10.3 Oral - Market size and forecast 2024-2029
Chart on Oral - Market size and forecast 2024-2029 ($ million)
Data Table on Oral - Market size and forecast 2024-2029 ($ million)
Chart on Oral - Year-over-year growth 2024-2029 (%)
Data Table on Oral - Year-over-year growth 2024-2029 (%)
10.4 Injection - Market size and forecast 2024-2029
Chart on Injection - Market size and forecast 2024-2029 ($ million)
Data Table on Injection - Market size and forecast 2024-2029 ($ million)
Chart on Injection - Year-over-year growth 2024-2029 (%)
Data Table on Injection - Year-over-year growth 2024-2029 (%)
10.5 Transdermal - Market size and forecast 2024-2029
Chart on Transdermal - Market size and forecast 2024-2029 ($ million)
Data Table on Transdermal - Market size and forecast 2024-2029 ($ million)
Chart on Transdermal - Year-over-year growth 2024-2029 (%)
Data Table on Transdermal - Year-over-year growth 2024-2029 (%)
10.6 Market opportunity by Route of Administration
Market opportunity by Route of Administration ($ million)
Data Table on Market opportunity by Route of Administration ($ million)
11 Market Segmentation by End-user
11.1 Market segments
Chart on End-user - Market share 2024-2029 (%)
Data Table on End-user - Market share 2024-2029 (%)
11.2 Comparison by End-user
Chart on Comparison by End-user
Data Table on Comparison by End-user
11.3 Hospital pharmacy - Market size and forecast 2024-2029
Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
11.4 Retail pharmacy - Market size and forecast 2024-2029
Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Retail pharmacy - Year-over-year growth 2024-2029 (%)
11.5 Online pharmacy - Market size and forecast 2024-2029
Chart on Online pharmacy - Market size and forecast 2024-2029 ($ million)
Data Table on Online pharmacy - Market size and forecast 2024-2029 ($ million)
Chart on Online pharmacy - Year-over-year growth 2024-2029 (%)
Data Table on Online pharmacy - Year-over-year growth 2024-2029 (%)
11.6 Market opportunity by End-user
Market opportunity by End-user ($ million)
Data Table on Market opportunity by End-user ($ million)
12 Customer Landscape
12.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
13 Geographic Landscape
13.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2024-2029 (%)
Data Table on Market share By Geographical Landscape 2024-2029 (%)
13.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
13.3 North America - Market size and forecast 2024-2029
Chart on North America - Market size and forecast 2024-2029 ($ million)
Data Table on North America - Market size and forecast 2024-2029 ($ million)
Chart on North America - Year-over-year growth 2024-2029 (%)
Data Table on North America - Year-over-year growth 2024-2029 (%)
13.4 Europe - Market size and forecast 2024-2029
Chart on Europe - Market size and forecast 2024-2029 ($ million)
Data Table on Europe - Market size and forecast 2024-2029 ($ million)
Chart on Europe - Year-over-year growth 2024-2029 (%)
Data Table on Europe - Year-over-year growth 2024-2029 (%)
13.5 Asia - Market size and forecast 2024-2029
Chart on Asia - Market size and forecast 2024-2029 ($ million)
Data Table on Asia - Market size and forecast 2024-2029 ($ million)
Chart on Asia - Year-over-year growth 2024-2029 (%)
Data Table on Asia - Year-over-year growth 2024-2029 (%)
13.6 Rest of World (ROW) - Market size and forecast 2024-2029
Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
13.7 US - Market size and forecast 2024-2029
Chart on US - Market size and forecast 2024-2029 ($ million)
Data Table on US - Market size and forecast 2024-2029 ($ million)
Chart on US - Year-over-year growth 2024-2029 (%)
Data Table on US - Year-over-year growth 2024-2029 (%)
13.8 Germany - Market size and forecast 2024-2029
Chart on Germany - Market size and forecast 2024-2029 ($ million)
Data Table on Germany - Market size and forecast 2024-2029 ($ million)
Chart on Germany - Year-over-year growth 2024-2029 (%)
Data Table on Germany - Year-over-year growth 2024-2029 (%)
13.9 Canada - Market size and forecast 2024-2029
Chart on Canada - Market size and forecast 2024-2029 ($ million)
Data Table on Canada - Market size and forecast 2024-2029 ($ million)
Chart on Canada - Year-over-year growth 2024-2029 (%)
Data Table on Canada - Year-over-year growth 2024-2029 (%)
13.10 China - Market size and forecast 2024-2029
Chart on China - Market size and forecast 2024-2029 ($ million)
Data Table on China - Market size and forecast 2024-2029 ($ million)
Chart on China - Year-over-year growth 2024-2029 (%)
Data Table on China - Year-over-year growth 2024-2029 (%)
13.11 Japan - Market size and forecast 2024-2029
Chart on Japan - Market size and forecast 2024-2029 ($ million)
Data Table on Japan - Market size and forecast 2024-2029 ($ million)
Chart on Japan - Year-over-year growth 2024-2029 (%)
Data Table on Japan - Year-over-year growth 2024-2029 (%)
13.12 UK - Market size and forecast 2024-2029
Chart on UK - Market size and forecast 2024-2029 ($ million)
Data Table on UK - Market size and forecast 2024-2029 ($ million)
Chart on UK - Year-over-year growth 2024-2029 (%)
Data Table on UK - Year-over-year growth 2024-2029 (%)
13.13 France - Market size and forecast 2024-2029
Chart on France - Market size and forecast 2024-2029 ($ million)
Data Table on France - Market size and forecast 2024-2029 ($ million)
Chart on France - Year-over-year growth 2024-2029 (%)
Data Table on France - Year-over-year growth 2024-2029 (%)
13.14 India - Market size and forecast 2024-2029
Chart on India - Market size and forecast 2024-2029 ($ million)
Data Table on India - Market size and forecast 2024-2029 ($ million)
Chart on India - Year-over-year growth 2024-2029 (%)
Data Table on India - Year-over-year growth 2024-2029 (%)
13.15 Italy - Market size and forecast 2024-2029
Chart on Italy - Market size and forecast 2024-2029 ($ million)
Data Table on Italy - Market size and forecast 2024-2029 ($ million)
Chart on Italy - Year-over-year growth 2024-2029 (%)
Data Table on Italy - Year-over-year growth 2024-2029 (%)
13.16 South Korea - Market size and forecast 2024-2029
Chart on South Korea - Market size and forecast 2024-2029 ($ million)
Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
Chart on South Korea - Year-over-year growth 2024-2029 (%)
Data Table on South Korea - Year-over-year growth 2024-2029 (%)
13.17 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)
14 Drivers, Challenges, and Opportunity/Restraints
14.1 Market drivers
14.2 Market challenges
14.3 Impact of drivers and challenges
Impact of drivers and challenges in 2024 and 2029
14.4 Market opportunities/restraints
15 Competitive Landscape
15.1 Overview
15.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
15.3 Landscape disruption
Overview on factors of disruption
15.4 Industry risks
Impact of key risks on business
16 Competitive Analysis
16.1 Companies profiled
16.2 Company ranking index
16.3 Market positioning of companies
Matrix on companies position and classification
16.4 AB Science SA
AB Science SA - Overview
AB Science SA - Product / Service
AB Science SA - Key offerings
SWOT
16.5 AbbVie Inc.
AbbVie Inc. - Overview
AbbVie Inc. - Product / Service
AbbVie Inc. - Key news
AbbVie Inc. - Key offerings
SWOT
16.6 Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. - Overview
Acadia Pharmaceuticals Inc. - Product / Service
Acadia Pharmaceuticals Inc. - Key offerings
SWOT
16.7 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
SWOT
16.8 Biogen Inc.
Biogen Inc. - Overview
Biogen Inc. - Product / Service
Biogen Inc. - Key offerings
SWOT
16.9 F. Hoffmann La Roche Ltd.
F. Hoffmann La Roche Ltd. - Overview
F. Hoffmann La Roche Ltd. - Business segments
F. Hoffmann La Roche Ltd. - Key news
F. Hoffmann La Roche Ltd. - Key offerings
F. Hoffmann La Roche Ltd. - Segment focus
SWOT
16.10 GlaxoSmithKline Plc
GlaxoSmithKline Plc - Overview
GlaxoSmithKline Plc - Business segments
GlaxoSmithKline Plc - Key news
GlaxoSmithKline Plc - Key offerings
GlaxoSmithKline Plc - Segment focus
SWOT
16.11 H Lundbeck AS
H Lundbeck AS - Overview
H Lundbeck AS - Product / Service
H Lundbeck AS - Key offerings
SWOT
16.12 Johnson and Johnson Services Inc.
Johnson and Johnson Services Inc. - Overview
Johnson and Johnson Services Inc. - Business segments
Johnson and Johnson Services Inc. - Key news
Johnson and Johnson Services Inc. - Key offerings
Johnson and Johnson Services Inc. - Segment focus
SWOT
16.13 Merck and Co. Inc.
Merck and Co. Inc. - Overview
Merck and Co. Inc. - Business segments
Merck and Co. Inc. - Key news
Merck and Co. Inc. - Key offerings
Merck and Co. Inc. - Segment focus
SWOT
16.14 Mitsubishi Chemical Corp.
Mitsubishi Chemical Corp. - Overview
Mitsubishi Chemical Corp. - Business segments
Mitsubishi Chemical Corp. - Key offerings
Mitsubishi Chemical Corp. - Segment focus
SWOT
16.15 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
SWOT
16.16 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
SWOT
16.17 Sanofi SA
Sanofi SA - Overview
Sanofi SA - Business segments
Sanofi SA - Key news
Sanofi SA - Key offerings
Sanofi SA - Segment focus
SWOT
16.18 Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. - Overview
Teva Pharmaceutical Industries Ltd. - Business segments
Teva Pharmaceutical Industries Ltd. - Key news
Teva Pharmaceutical Industries Ltd. - Key offerings
Teva Pharmaceutical Industries Ltd. - Segment focus
SWOT
17 Appendix
17.1 Scope of the report
17.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
17.3 Currency conversion rates for US$
Currency conversion rates for US$
17.4 Research methodology
17.5 Data procurement
17.6 Data validation
17.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
17.8 Data synthesis
17.9 360 degree market analysis
360 degree market analysis
17.10 List of abbreviations